Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Septerna, Inc. ( (SEPN) ).
On August 21, 2025, Septerna, Inc. announced the dosing of the first participants in a Phase 1 clinical trial for SEP-631, an oral small molecule targeting MRGPRX2 for treating mast cell-driven diseases like chronic spontaneous urticaria. The trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SEP-631 in healthy volunteers, potentially offering a new oral treatment option for patients with significant unmet medical needs.
The most recent analyst rating on (SEPN) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Septerna, Inc. stock, see the SEPN Stock Forecast page.
Spark’s Take on SEPN Stock
According to Spark, TipRanks’ AI Analyst, SEPN is a Neutral.
Septerna, Inc. benefits significantly from its collaboration with Novo Nordisk, enhancing its strategic positioning. However, financial performance is constrained by operational inefficiencies and losses, while valuation metrics reflect challenges. Positive technical indicators provide some balance to the overall score.
To see Spark’s full report on SEPN stock, click here.
More about Septerna, Inc.
Septerna, Inc. is a clinical-stage biotechnology company specializing in G protein-coupled receptor (GPCR) drug discovery. The company focuses on developing novel oral small molecule drug candidates for various therapeutic areas, including endocrinology, immunology, inflammation, and metabolic diseases, using its proprietary Native Complex Platform.
Average Trading Volume: 380,614
Technical Sentiment Signal: Strong Sell
Current Market Cap: $487.3M
See more data about SEPN stock on TipRanks’ Stock Analysis page.